Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
| July 11, 2024
Read More
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
| June 13, 2024
Read More
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
| May 28, 2024
Read More
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
| May 13, 2024
Read More
Vivani Medical to Present at TIDES Conference 2024
| May 9, 2024
Read More
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
| March 26, 2024
Read More
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
| March 6, 2024
Read More
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
| March 1, 2024
Read More
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
| February 28, 2024
Read More
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
| November 14, 2023
Read More
Blog Navigation
Contact Us
To learn more about Vivani or LIBERATE-1, the upcoming First-in-Human trial of our long-term GLP-1 implant, please fill out the form.